Paclitaxel (Ovarian Cancer) – Analysis and Forecasts to 2020

Paclitaxel (Ovarian Cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, "Paclitaxel (Ovarian Cancer) - Analysis and Forecasts to 2020” provides Paclitaxel sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of Paclitaxel including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Paclitaxel including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2002-2020 for Paclitaxel in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late Menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7
3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11
4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12
5 Paclitaxel 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.3.1 First Line of Treatment of Advanced Ovarian Cancer 15
5.3.2 Second Line of Treatment of Advanced Ovarian Cancer 16
5.4 Approval History of Taxol 17
5.5 Factors Affecting Sales 17
5.5.1 Patent Expiry of Taxol 17
5.5.2 Increase in generic competition 17
5.5.3 Highest Efficacy of paclitaxel in Combination with cisplatin for the First Line Treatment 17
5.5.4 Better efficacy of paclitaxel in combination with Avastin for advanced ovarian cancer. 17
5.6 Drug Evaluation 18
5.6.1 Drug Risk Benefit Score 18
5.7 Sales Forecasts 20
5.7.1 Target Patient Pool of Paclitaxel 20
5.7.2 Dosing 20
5.7.3 Market Penetration 21
5.7.4 Annual Cost of Therapy 21
5.7.5 Sales Projections of Paclitaxel 22
6 Ovarian Cancer Market: Appendix 31
6.1 Market Definitions 31
6.2 List of Abbreviations 31
6.3 Research Methodology 31
6.3.1 Coverage 31
6.3.2 Secondary Research 32
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 34
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 35
6.4 Contact Us 35
6.5 Disclaimer 35
6.6 Sources 35